Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.56 |
| ▸ | ANPEP | P15144 | 2/20 | 0.53 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.53 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.48 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.44 |
| ▸ | LAP3 | P28838 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.39 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.39 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2029393 | 1.00 | SLC7A5 (0.56) | SLC7A5ANPEPDNPEPSLC1A3SLC1A2 | |
| SCHEMBL1247473 | 1.00 | SLC7A5 (0.56) | SLC7A5ANPEPDNPEPSLC1A3SLC1A2 | |
| SCHEMBL762515 | 1.00 | SLC7A5 (0.56) | SLC7A5ANPEPDNPEPSLC1A3SLC1A2 | |
| SCHEMBL2031045 | 1.00 | SLC7A5 (0.56) | SLC7A5ANPEPDNPEPSLC1A3SLC1A2 | |
| SCHEMBL2033220 | 1.00 | SLC7A5 (0.56) | SLC7A5ANPEPDNPEPSLC1A3SLC1A2 | |
| SCHEMBL2034368 | 1.00 | SLC7A5 (0.56) | SLC7A5ANPEPDNPEPSLC1A3SLC1A2 | |
| Hydrochloric Acid SCHEMBL9514577 | 0.98 | SLC7A5 (0.54) | SLC7A5ANPEPDNPEPSLC1A3SLC1A2 | |
| Hydrochloric Acid SCHEMBL737245 | 0.98 | SLC7A5 (0.54) | SLC7A5ANPEPDNPEPSLC1A3SLC1A2 | |
| Hydrochloric Acid SCHEMBL9514582 | 0.98 | SLC7A5 (0.54) | SLC7A5ANPEPDNPEPSLC1A3SLC1A2 | |
| Hydrochloric Acid SCHEMBL9370266 | 0.98 | SLC7A5 (0.54) | SLC7A5ANPEPDNPEPSLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 303 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3110828-B1 | CONTINUOUS FLOW PEPTIDE SYNTHESIS | UNIV SZEGEDI (HU) | 2020-12-09 | — | — | EP | claimed |
| US-9976133-B2 | Synzymes | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-22 | — | — | US | claimed |
| US-20170022487-A1 | SYNTHETIC CATALYTIC MIMICS OF ESTERASES, LIPASES OR DESATURASES | UNIV CALIFORNIA (US) | 2017-01-26 | — | — | US | claimed |
| WO-2015153730-A2 | SYNTHETIC CATALYTIC MIMICS OF ESTERASES, LIPASES OR DESATURASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-10-08 | — | — | WO | claimed |
| US-20150175993-A1 | NOVEL SYNZYMES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-06-25 | — | — | US | claimed |
| EP-2864349-A2 | DYNAMIC BIOMIMETIC SYNZYME CATALYST, CATALYSIS, AND CATALYTIC SYSTEMS | The Regents of The University of California (US) | 2015-04-29 | — | — | EP | claimed |
| WO-2013192430-A2 | DYNAMIC BIOMIMETIC SYNZYME CATALYST, CATALYSIS, AND CATALYTIC SYSTEMS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-12-27 | — | — | WO | claimed |
| US-12558412-B2 | Vaccination of immunocompromised subjects | Seqirus UK Limited (GB) | 2026-02-24 | — | — | US | disclosed |
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | UNIVERSITY OF CONNECTICUT (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250302762-A1 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250302971-A1 | Therapeutic Nanomaterials | UNIV CONNECTICUT (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250269008-A1 | VACCINATION OF IMMUNOCOMPROMISED SUBJECTS | NOVARTIS AG (CH) | 2025-08-28 | — | — | US | disclosed |
| US-20250242011-A1 | VACCINATION OF IMMUNOCOMPROMISED SUBJECTS | Seqirus UK Limited (GB) | 2025-07-31 | — | — | US | disclosed |
| EP-0216539-A2 | Novel amino acid derivatives | Kissei Pharmaceutical Co. Ltd. (JP) | 1987-04-01 | — | — | EP | disclosed |
| EP-0206807-A2 | Novel amino acid derivatives | Kissei Pharmaceutical Co. Ltd. (JP) | 1986-12-30 | — | — | EP | disclosed |
| EP-0200406-A2 | Novel amino acid derivatives | Kissei Pharmaceutical Co. Ltd. (JP) | 1986-11-05 | — | — | EP | disclosed |
| EP-0190891-A2 | Novel amino acid derivatives | Kissei Pharmaceutical Co. Ltd. (JP) | 1986-08-13 | — | — | EP | disclosed |
| US-4318847-A | ENZYME INHIBITORS | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1982-03-09 | — | — | US | disclosed |
| US-4240975-A | USED AS ENZYME INHIBITOR, ANTIFERTILITY AGENT, AND ENHANCES THE ANTITUMOR EFFECT OF BLEOMYCIN | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1980-12-23 | — | — | US | disclosed |
| US-4189604-A | PEPTIDASE ENZYME INHIBITORS | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1980-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302971-A1 | Therapeutic Nanomaterials | TIE1, TEKT1, POLRMT | SLC7A5 921/4885ANPEP 205/4885DNPEP 558/4885 |
| US-12558412-B2 | Vaccination of immunocompromised subjects | ICOS, IL15, CD4 | SLC7A5 837/4885ANPEP 2495/4885DNPEP 4277/4885 |
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | EPCAM, CD47, JAK2 | SLC7A5 1405/4885ANPEP 2209/4885DNPEP 1372/4885 |
| US-20250302762-A1 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | JAK2, JAK1, CHMP4B | SLC7A5 1050/4885ANPEP 4326/4885DNPEP 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.